MIM
SWTX

Monashee Investment Management’s SpringWorks Therapeutics SWTX Stock Holding History

Monashee Investment Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-73,949
Closed -$2.7M – 122
2023
Q4 		$2.7M Buy
+73,949
New +$1.93M 0.48% 21
2021
Q4 		– Sell
-56,766
Closed -$3.6M – 112
2021
Q3 		$3.6M Buy
56,766
+11,766
+26% +$907K 0.67% 30
2021
Q2 		$3.71M Buy
45,000
+10,000
+29% +$759K 0.44% 53
2021
Q1 		$2.58M Buy
+35,000
New +$2.74M 0.4% 69
2019
Q4 		– Sell
-82,803
Closed -$1.79M – 125
2019
Q3 		$1.79M Buy
+82,803
New +$1.96M 0.82% 42

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Monashee Investment Management's SWTX Position: Q1 2024 in Review

Monashee Investment Management sold out of SpringWorks Therapeutics (SWTX) in Q1 2024, closing a stake of 73,949 shares — an estimated $2.7M sold.

Monashee Investment Management first reported a position in SWTX in Q3 2019 and held it in 5 quarters. The position peaked at $3.71M in Q2 2021. 217 funds tracked by Wall St. Rank hold SWTX as of Q1 2024.

  • Monashee Investment Management reported no remaining SpringWorks Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Monashee Investment Management sold 73,949 SpringWorks Therapeutics shares in Q1 2024, an estimated $2.7M.
  • Monashee Investment Management first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 5 quarters.
  • Monashee Investment Management's SpringWorks Therapeutics position peaked at $3.71M in Q2 2021.
  • 217 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2024.

Based on Monashee Investment Management's 13F filing for Q1 2024, filed 14 May 2024.